CHGCF - Roche's Enspryng OK'd in Europe as first at-home treatment for neuromyelitis optica spectrum disorder

Roche (RHHBY) has been granted Marketing Authorization from the European Commission for Enspryng (satralizumab), created by Chugai Pharmaceutical (CHGCF), as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder ((NMOSD)), as a monotherapy or in combination with immunosuppressive therapy.NMOSD is an autoimmune disease of the central nervous system characterized by inflammatory lesions in the optic nerves and spinal cord, and causes permanent neurological disability.Enspryng is the first treatment approved in EU for adolescents from 12 years of age with NMOSD. Enspryng is the first approved medicine applying Chugai’s proprietary recycling antibody technology which can be self-administered at home every four weeks.The approval is based on the results from two global phase III clinical studies: SAkuraSky Study and SAkuraStar Study.Enspryng is designed to prevent NMOSD relapses by inhibiting IL-6 signal signaling, which is a key driver in

For further details see:

Roche’s Enspryng OK'd in Europe as first at-home treatment for neuromyelitis optica spectrum disorder